{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:03Z","timestamp":1793898243078,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32141004"],"award-info":[{"award-number":["32141004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaut.2026.103578","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:17:14Z","timestamp":1780064234000},"page":"103578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"161","author":[{"given":"Ru","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2026.103578_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2026.103578_bib2","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"H\u00f8ib\u00f8","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2026.103578_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.berh.2017.09.007","article-title":"Drivers of the immunopathogenesis in systemic lupus erythematosus","volume":"31","author":"Rose","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103578_bib4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/ard-2023-225319","article-title":"Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations","volume":"83","author":"Kostopoulou","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2026.103578_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erthematosus for new therapies","volume":"27","author":"Allen","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jaut.2026.103578_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4049\/jimmunol.160.1.51","article-title":"A new role for B cells in systemic autoimmunity: b cells promote spontaneous T cell activation in MRL-lpr\/lpr mice","volume":"160","author":"Chan","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2026.103578_bib7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"D\u00f6rner","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103578_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2026.103578_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113040","article-title":"Bruton's tyrosine kinase: a promising target for treating systemic lupus erythematosus","volume":"142","author":"Ding","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jaut.2026.103578_bib10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3389\/fimmu.2017.01986","article-title":"Bruton's tyrosine kinase, a component of B cell signaling pathways, has multiple roles in the pathogenesis of lupus","volume":"8","author":"Satterthwaite","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2026.103578_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.jaut.2026.103578_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jaut.2026.103578_bib13","doi-asserted-by":"crossref","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2020-CT132","article-title":"Abstract CT132: orelabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties","volume":"80","author":"Zhang","year":"2020","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jaut.2026.103578_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2026.103578_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999\u20132014)","volume":"57","author":"Jorge","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2026.103578_bib16","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.40512","article-title":"Lupus \u2014 an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000\u20132015","volume":"70","author":"Yen","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2026.103578_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2026.103578_bib18","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2026.103578_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2026.103578_bib20","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma: a phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.jaut.2026.103578_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaut.2026.103578_bib22","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2026.103578_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.jaut.2026.103578_bib24","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2026.103578_bib25","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2026.103578_bib26","unstructured":"X. Montalban, D.L. Arnold, M.S. Weber, I. Staikov, K. Piasecka-Stryczynska, E.C. Martin, et al., Clinical relapse rates in relapsing MS patients treated with the BTK inhibitor evobrutinib: results of an open-label extension to a phase II study, Presented at European Charcot Foundation 28th Annual Meeting; 15\u201319 November 2020; Virtual."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:09:31Z","timestamp":1783091371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"alternative-id":["S0896841126000569"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103578","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103578"}}